Capricor Therapeutics Inc Stock Price, News & Analysis

Capricor Therapeutics (NASDAQ: CAPR) presented findings on its exosome-mediated mRNA delivery approach for SARS-CoV-2 at the ISEV Annual Meeting, highlighting its potential to address challenges posed by COVID-19 variants. CEO Linda Marbán noted that their multivalent mRNA vaccine generates lasting immune responses. This data emphasizes Capricor's innovative platform, which aims to deliver targeted therapies across various diseases. The meeting runs from May 18-21, 2021, with on-demand access to sessions until June 14, 2021.

Capricor Therapeutics (NASDAQ: CAPR) announced significant developments in the first quarter of 2021, including a net loss of $5.2 million. The company executed a licensing agreement with Johns Hopkins University, advancing its engineered exosome technology. Capricor plans to file an IND for its SARS-CoV-2 vaccine and expects top-line data from its INSPIRE clinical trial by Q3 2021. The company raised $12.6 million through stock offerings and reported cash reserves of approximately $41.9 million, which should suffice to cover expenses through at least Q2 2023.

Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán, Ph.D., will present at the ASGCT's 24th annual meeting, held virtually from May 11-14, 2021. The session, titled Therapeutic Applications of Extracellular Vesicles, focuses on exosome delivery of SARS-CoV-2 vaccines. Marbán emphasized the company's leadership in exosome delivery for COVID-19 vaccination. Capricor is known for developing cell- and exosome-based therapeutics, including its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and COVID-19 related cytokine storms.

Capricor Therapeutics (NASDAQ: CAPR) will announce its financial results for Q1 2021 on May 13, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the financial performance and recent corporate updates. Capricor focuses on cell- and exosome-based therapies, particularly its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and cytokine storms in COVID-19 patients. The company is also advancing its exosome platform technology for various diseases.

Capricor Therapeutics (NASDAQ: CAPR) has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University to integrate engineered exosomes into its therapeutic portfolio. This agreement allows Capricor to develop, manufacture, and commercialize exosome technology for vaccines and therapeutics. CEO Linda Marbán emphasized that this milestone will facilitate expansion into areas of significant unmet medical needs. The collaboration builds on over a decade of research and aims to enhance therapeutic delivery systems using exosomes.

Capricor Therapeutics (NASDAQ: CAPR) reported a net loss of approximately $4.2 million, or $0.21 per share, for Q4 2020, compared to a loss of $1.5 million in Q4 2019. The total net loss for 2020 was about $13.7 million, or $0.88 per share, up from $7.6 million in 2019. The company holds $32.7 million in cash and equivalents as of December 31, 2020, significantly higher than $9.9 million in 2019. The firm is advancing its engineered exosome platform technology and preparing for a pre-IND meeting with the FDA regarding a multivalent vaccine. Top-line data from the Phase II INSPIRE trial are expected in Q3 2021.

Capricor Therapeutics (NASDAQ: CAPR) announced new preclinical data highlighting the effectiveness of its exosome-based mRNA vaccine for COVID-19. The study shows enhanced mRNA expression with lower toxicity compared to lipid nanoparticles, demonstrating functional RNA delivery in live animals. Key findings include real-time imaging of mRNA delivery and no adverse effects. Capricor plans to engage with the FDA regarding clinical development strategies, indicating significant advancements in their therapeutic pipeline.

Capricor Therapeutics (NASDAQ: CAPR) will report its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET that day. The company focuses on developing cell- and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and COVID-19. Investors can access more details during the call and via the company's website.

Capricor Therapeutics (NASDAQ: CAPR) has licensed technology from Johns Hopkins University for a novel imaging-based serology test for COVID-19. This platform effectively analyzes patient antibodies to various SARS-CoV-2 proteins, potentially improving serology testing by reducing false positives and negatives. Key findings demonstrate the technology’s capability to capture antibodies in their native conformations. The company plans to advance its COVID-19 vaccine development and engage with the FDA regarding future clinical steps.